Liberatebio

Liberate Bio's RAPTOR™ platform successfully advances its lead in vivo CAR-M candidate through early clinical trials, demonstrating superior safety and efficacy compared to existing CAR-T therapies, particularly for autoimmune diseases. A major pharmaceutical company acquires Liberate Bio for its platform technology and pipeline, valuing it at over $1.2B, a 4x multiple on the current valuation.

Liberate Bio successfully completes IND-enabling studies and initiates its first clinical trial in late 2026, showing promising early safety data. The company secures a Series A or B round at a modest step-up, reaching a valuation of approximately $465M, as it continues to de-risk its platform and pipeline in a highly competitive and capital-intensive environment.

Liberate Bio faces significant challenges in clinical translation, either due to unexpected safety issues, limited efficacy, or an inability to differentiate from incumbent therapies. The high capital requirements lead to a down round or failure to secure further funding, resulting in a valuation collapse to $62M or less, wiping out most common stock value due to liquidation preferences.